Using ultrasound to treat obstructive hypertrophic cardiomyopathy
Minimally Invasive High Intensity Therapeutic Ultrasound for the Treatment of Obstructive Hypertrophic Cardiomyopathy
This study is testing a new, less invasive treatment for people with obstructive hypertrophic cardiomyopathy (oHCM) that uses ultrasound to help reduce heart muscle blockage, making it a safer option than traditional surgery.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Coridea, LLC NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11063380 on NIH RePORTER |
What this research studies
This research investigates a new treatment for obstructive hypertrophic cardiomyopathy (oHCM), a serious inherited heart condition. The approach involves using a minimally invasive catheter that delivers high-intensity therapeutic ultrasound to target and reduce the obstruction in the heart muscle. This method aims to avoid the complications associated with traditional surgical treatments, which can be highly invasive and carry significant risks. By focusing on a safer delivery method, the research seeks to improve outcomes for patients who are currently not receiving effective treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with obstructive hypertrophic cardiomyopathy who have not responded to medical management and are considered for septal reduction therapy.
Not a fit: Patients with non-obstructive forms of hypertrophic cardiomyopathy or those who are not candidates for any form of septal reduction therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a safer and more effective treatment option for patients with obstructive hypertrophic cardiomyopathy.
How similar studies have performed: While traditional surgical approaches have been widely used, this novel ultrasound technique represents a new and untested method in the treatment of obstructive hypertrophic cardiomyopathy.
Where this research is happening
New York, United States
- Coridea, LLC — New York, United States (Active)
Researchers
- Principal investigator: Levin, Howard — Coridea, LLC
- Study coordinator: Levin, Howard
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.